Continuing Stimulant Treatment for Patients with Suspected ADHD

Diagnosis Verification and Treatment Justification

The American Academy of Child and Adolescent Psychiatry recommends confirming ADHD diagnosis with moderate-to-severe functional impairment in at least two different settings before continuing stimulant medication 1, 2
A complete psychiatric and medical history should be obtained from previous prescribers, including original diagnostic evaluation, baseline symptom severity, and treatment response documentation 1, 2
The diagnosis of ADHD should be confirmed with collateral information from at least two sources in different settings, such as workplace/home for adults or school/home for children 1, 2
Current functional impairment should be documented in academic/occupational, social, and family domains to justify continued treatment 1, 2
Previous medication trials should be reviewed to understand which stimulants were effective and at what doses 3

The American Academy of Child and Adolescent Psychiatry recommends monthly appointments for the first 1-3 months after initiating stimulant treatment, with monitoring of cardiovascular parameters and assessment for adverse effects 4, 6
Standardized rating scales, such as the ADHD-RS, should be used to objectively measure current symptom severity and treatment response 1, 2, 4
Appointments should be continued every 3 months minimum once stability is established, with reassessment of diagnosis and need for continued treatment at least annually 4, 3

Methylphenidate formulations can be used with typical adult dosing of 5-20 mg three times daily for immediate-release, and long-acting formulations providing 8-12 hours of coverage 6, 4
Amphetamine formulations, such as dextroamphetamine, can be used with dosing of 5 mg three times daily to 20 mg twice daily for adults 6
If current stimulant is inadequate, switching to the alternative stimulant class (methylphenidate to amphetamine or vice versa) should be considered before abandoning stimulants entirely 4

Stimulant trials can be initiated first in patients with comorbid depression/anxiety, unless depression is severe 6
Stimulants remain effective in patients with comorbid anxiety, and can be used with SSRI addition if anxiety persists after ADHD symptoms improve 6
In patients with comorbid tic disorders, stimulants are safe and effective, and can be continued unless tics significantly worsen 6, 7

Atomoxetine can be initiated at 40 mg/day, titrated to maximum 100 mg/day over several weeks, and is preferred for patients with substance use disorders, comorbid anxiety, or tic disorders 4, 7
Alpha-2 agonists, such as guanfacine and clonidine, can be used as monotherapy or augmentation to stimulants, with careful monitoring of cardiac history 4